- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01199250
Biomarkers in Samples From Patients With Endometrial Cancer
Specialized Program of Research Excellence (SPORE) in Endometrial Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Assess the frequency and spectrum of mutations in fibroblast growth factor receptor 2 (FGFR2) in low-, intermediate-, and/or high-risk endometrioid endometrial cancer from GOG-0210. (Project 1) II. Determine the relationship between FGFR2 mutation and clinicopathologic variables including disease-free and overall survival in low-, intermediate-, and/or high-risk endometrial cancer from GOG-0210. (Project 1) III. Identify the cognate FGF ligands and receptors expressed in normal endometrium and endometrial cancers, and examine their expression on multiple tissue microarrays for GOG-0210 to determine their association with clinical outcome. (Project 1) IV. Identify epigenetic biomarkers (differential methylation of CpG island loci) associated with recurrence and disease progression in endometrioid endometrial cancer from Washington University School of Medicine (WUSM). (Project 2) V. Confirm epigenetic biomarkers (differential methylation of CpG island loci) associated with recurrent and disease progression in endometrioid endometrial cancer from GOG-0210. (Project 2) VI. Define the performance (sensitivity and specificity) of epigenetic biomarkers associated with recurrence and disease progression in endometrioid endometrial cancer from an independent cohort of cases from GOG-0210. (Project 2) VII. Develop a molecular screening regimen to compliment family history risk assessment to identify carriers of Hereditary Non-Polyposis Colorectal Cancer (HNPCC)-related and other forms of inherited endometrial cancer from GOG-0210 that was not ascertained by family history. (Project 3) VIII. Estimate the prevalence of HNPCC-related and other forms of inherited endometrial cancer in GOG-0210. (Project 3) IX. Define the relationship between defective DNA mismatch repair and clinical and epidemiological factors in GOG-0210. (Project 3) X. Determine the clinicopathologic significance of mismatch-repair defects including associations with disease-free and overall survival in GOG-0210. (Project 3) XI. Assess expression of five candidate ERK1/2 substrates in the normal endometrium, primary endometrial cancers (from WUSM and GOG-0210) and endometrial cancer cell lines and determine if substrate phosphorylation is ERK-dependent. (Project 4) XII. Determine the relationship between ERK substrate-phosphorylation status and upstream ERK-signaling pathway activation in primary endometrial cancers from WUSM and GOG-0210. (Project 4 XIII. Determine the clinicopathologic significance of ERK substrate expression in primary endometrial cancers from WUSM and GOG-0210. (Project 4) XIV. Explore GSK3/3 inhibition as a therapeutic treatment of endometrial cancer and assess the role of inhibiting other ERK substrates in endometrial cell lines. (Project 4) XV. Explore the predictive and prognostic accuracy of a panel of single nucleotide polymorphisms alone and with informative clinical, surgical, and pathologic variables in a cohort of Caucasian women with stage IB or IC vs IIIC endometrioid endometrial cancer from WUSM and GOG-0210. (Project 5)
OUTLINE: This is a multicenter study.
Previously collected samples are analyzed for biomarker and other laboratory analyses.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19103
- Gynecologic Oncology Group
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Samples available from one of the following:
- GOG-0210
- Washington University School of Medicine Siteman Cancer Center
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Basic science (biomarker analysis)
Previously collected samples are analyzed for biomarker and other laboratory analyses.
|
Correlative studies
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical sensitivity and specificity of epigenetic biomarkers in a cohort of blind samples (Project 2)
Time Frame: 1 month
|
ROC curves used to describe the discriminatory characteristics of candidate biomarkers.
From the competing risk model, the coefficients of the clinicopathological covariates and the hypermethylation levels of each biomarker will indicate the association of these factors with each of the four types of survivals.
The significance of association will be indicated by P-values, and hazard rates will also be provided.
|
1 month
|
Confirmation of CpG island loci frequently hypermethylated in EECs exhibiting recurrence (Project 2)
Time Frame: 1 month
|
Proportion of methylated samples and 95% confidence interval calculated for each marker, recurrent and non-recurrent samples.
Will determine statistical significance of mean difference in DMH methylation levels between methylated and non-methylated samples on basis of two-sided two sample t-tests or nonparametric Wilcoxon tests (if normality is in question).
Binary methylation status tabulated with recurrence status to formulate 2 by 2 contingency table.
Existence of significant association indicated by a <0.05 p-value from Chi-square test or Fisher test (in case of small counts).
|
1 month
|
Development of a molecular screening regimen to compliment family history risk assessment for the detection of Lynch syndrome (Project 3)
Time Frame: 1 month
|
1 month
|
|
Expression of candidate ERK1/2 substrates in the normal endometrium, primary endometrial cancers and endometrial cancer cell lines dependence of substrate phosphorylation on ERK (Project 4)
Time Frame: 1 month
|
1 month
|
|
Frequency of Lynch syndrome-related endometrial cancer and relationships between inherited and acquired DNA mismatch repair defects and clinicopathologic variables (Project 3)
Time Frame: 1 month
|
1 month
|
|
GSK3β inhibition as a therapeutic treatment of endometrial cancer and role of inhibiting other ERK substrates in endometrial cancer cell lines (Project 4)
Time Frame: 1 month
|
1 month
|
|
Identification of cognate FGF ligands and receptors expressed in normal endometrium and endometrial cancers (Project 1)
Time Frame: 1 month
|
Loss of expression or overexpression for each of FGFs/FGFRs will be described using contingency tables and the overall between-group differences will be compared using Chi-square test or Fisher's exact test as appropriate.
For each marker, the nuclear positivity and cytoplasmic positivity will be evaluated separately.
Proportional hazards Cox models will be fitted for each FGFR receptor or FGF ligand to evaluate its effect on PFS, ECS, and OS.
Multivariate Cox model will be developed while considering biomarkers that have shown trend of significance in univariate analyses (permuted p < 0.2).
|
1 month
|
Identification of profiles of CpG island hypermethylation for stratifying subtypes of EECs (Project 2)
Time Frame: 1 month
|
Descriptive statistics including mean, median and standard deviation will be summarized for the recurrent and non-recurrent groups across the 54 samples.
Graphical presentation of the data will be provided by use of box-whisker plots and scatter plots.
|
1 month
|
Predictive and prognostic accuracy of a panel of SNPs alone and with informative clinical, surgical, and pathologic variables in a cohort of Caucasian women with stage IB or IC vs IIIC endometrioid endometrial cancer from WUSM and GOG-0210 (Project 5)
Time Frame: 1 month
|
1 month
|
|
Relationship between ERK substrate phosphorylation status and upstream ERK signaling pathway activation in primary endometrial cancers and clinicopathologic significance of ERK substrate expression(Project 4)
Time Frame: 1 month
|
The primary endpoints are protein amounts from quantitative Western blots and IHC-based ordinal scores describing intensity of staining and percentage of cells staining in the nucleus, cytoplasm and a combination of both locations.
|
1 month
|
Relationship between inherited variation in the MLH1 DNA repair gene and somatic (acquired) inactivation of MLH1 in sporadic endometrial cancer (Project 3)
Time Frame: 1 month
|
The primary association analysis for the case-control association study will be 2 x 2 contingency table analysis using chi squared tests.
The allele frequency for each SNP will be compared for all cases and controls.
|
1 month
|
Role of FGFR2 mutations in low, intermediate and high risk endometrial cancers (Project 1)
Time Frame: 1 month
|
Clinical outcome in FGFR2 mutation carriers will be compared with survival for women with no mutations.
Effect of the mutation over time using survival modeling also considered.
OS and PFS described using Cox model.
PFI time and ECS time described using competing risks model.
Prognostic factors will be evaluated in univariate and multivariate analyses.
Variables associated with each primary endpoint (OS, DFS, PHI and ECS) at the 10% level on the basis of univariate models will be introduced in the multivariate models.
Significance levels for all analyses will be set at a p-value of 0.05.
|
1 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Paul Goodfellow, Gynecologic Oncology Group
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Metabolic Diseases
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Genetic Diseases, Inborn
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Colorectal Neoplasms
- Neoplastic Syndromes, Hereditary
- DNA Repair-Deficiency Disorders
- Colorectal Neoplasms, Hereditary Nonpolyposis
- Endometrial Neoplasms
Other Study ID Numbers
- GOG-8020 (Other Identifier: CTEP)
- U10CA027469 (U.S. NIH Grant/Contract)
- P50CA134254 (U.S. NIH Grant/Contract)
- R01CA071754 (U.S. NIH Grant/Contract)
- R21CA133295 (U.S. NIH Grant/Contract)
- U10CA037517 (U.S. NIH Grant/Contract)
- NCI-2011-02868 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- CDR0000684553
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lynch Syndrome
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHigh-Frequency Microsatellite Instability | Mismatch Repair Gene Mutation | Mutation-Negative Lynch Syndrome | Mutation-Positive Lynch SyndromeUnited States
-
San Raffaele UniversityUnita' di Gastroenterologia - Policlinico Universitario di Bari; Unita' di... and other collaboratorsRecruitingLynch Syndrome | MLH1 Gene Mutation | MSH2 Gene Mutation | MSH6 Gene Mutation | PMS2 Gene Mutation | Lynch Syndrome II | Small Bowel Adenocarcinoma | Lynch Syndrome IItaly
-
Tel-Aviv Sourasky Medical CenterRambam Health Care Campus; Rabin Medical Center; Sheba Medical Center; Soroka University...Not yet recruitingLynch Syndrome I (Site-specific Colonic Cancer)Israel
-
Piazza della Vittoria 14 Studio Medico - Ginecologia...Not yet recruitingLynch Syndrome | ContraceptionItaly
-
National Cancer Institute (NCI)RecruitingLynch SyndromeUnited States, Puerto Rico
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Imperial College LondonEnrolling by invitation
-
Second Affiliated Hospital, School of Medicine,...Completed
-
Hospital Clinic of BarcelonaFundacion Clinic per a la Recerca BiomédicaCompleted
-
PERROD GuillaumeNot yet recruiting
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States